Aytu Biopharma (AYTU) Receivables (2015 - 2026)

Aytu Biopharma (AYTU) has 12 years of Receivables data on file, last reported at $24.5 million in Q1 2026.

• On a quarterly basis, Receivables fell 38.97% year-over-year to $24.5 million in Q1 2026; TTM through Mar 2026 was $24.5 million, a 38.97% decrease from a year earlier, with the FY2025 full-year figure at $35.4 million, up 12.35% from the prior year.
• Receivables for Q1 2026 stood at $24.5 million, down from $30.9 million in the prior quarter.
• Over the last five years, Receivables for AYTU reached as high as $40.1 million in Q1 2025 and fell as low as $24.2 million in Q2 2022.
• Historically, Receivables has averaged $30.3 million across 5 years, with a median of $29.9 million in 2023.
• Across the five-year window, Receivables soared 34.2% in 2025 and plunged 38.97% in 2026, its largest moves.
• Year by year, Receivables stood at $25.5 million in 2022, then gained by 15.29% to $29.4 million in 2023, then rose by 6.13% to $31.2 million in 2024, then decreased by 0.9% to $30.9 million in 2025, then declined by 20.81% to $24.5 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $24.5 million in Q1 2026, $30.9 million in Q4 2025, and $33.2 million in Q3 2025.